Skip to main content
main-content

22-09-2020 | ESMO 2020 | Conference coverage | Video

Lorlatinib takes CROWN in head-to-head comparison with crizotinib

share
SHARE

Benjamin Solomon highlights the key messages of the CROWN study of lorlatinib in advanced, ALK-positive non-small-cell lung cancer and makes the case for using the agent upfront in these patients (3:42).

Read transcript

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.